The Thousand Oaks, Calif.-based company reported first-quarter results on Thursday, including an update on its weight loss drug in development, which led analysts to update their Amgen stock price ...
The S&P 500 jumped 1.3% on Friday, May 3, 2024, as the latest jobs report showed a cooling labor market, revitalizing hopes for a near-term interest rate cut.
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
On the earnings front, the biotech beat estimates with non-GAAP EPS of $3.96 vs. the expected $3.88. Total revenue of $7.45 billion was in line with analysts' consensus expectation. Its strong revenue ...
Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
, opens new tab is laying off more than 10% of its global workforce, an internal memo seen by Reuters on Monday shows, as it grapples with falling sales and an intensifying price war for electric ...
Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.